The U.S Food and Drug Administration (USFDA) has conducted an inspection at Unit-1 of Shilpa Medicare’s wholly owned subsidiary--Shilpa Pharma Lifesciences, located at Raichur from March 3, 2025 to March 7, 2025.
On conclusion of inspection, the company received 1 observation in form 483, which is procedural in nature. The company will closely work with the agency and remain committed to address this observation comprehensively within stipulated time.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
